DURHAM, N.C., May 31, 2016 — Treatment of rare indications is turning a promising corner as regulators and lawmakers boost incentives and guidance in these areas of unmet medical need. Three experts from Premier Research will look at financial aid, expedited reviews, and other avenues available to orphan drug developers in a webinar on Wednesday, June 1.

The hour-long session, starting at 11am EDT / 4pm GMT / 5pm CEST, will examine support available from global regulatory agencies and look at pending legislative initiatives. Attendees will hear from:

Angi Robinson, Executive Director for Strategic Development in Rare Disease & Pediatrics, who has overseen more than 30 pediatric and rare disease studies over the past 14 years.

Lisa Pitt, Vice President for Global Regulatory Affairs and a former FDA staffer who evaluated drugs for inherited metabolism disorders while working at the federal agency.

Juliet Moritz, Executive Director for Clinical Development Planning in Rare Diseases, whose 25-year clinical research career ranges from single-site studies to large, multinational trials.

After more than two decades of evolution, meaningful changes are appearing on the horizon for development of orphan drugs. Register today and see what these changes mean for the industry.

About Premier Research

Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, CNS, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.